Adding carboplatin to adjuvant epirubicin/cyclophosphamide followed by taxanes in early-stage triple-negative breast cancer

Clinical benefits on disease-free survival and overall survival with the addition of carboplatin to adjuvant epirubicin/cyclophosphamide followed by taxanes in early-stage triple-negative breast cancer